Search Results

Titan Pharmaceuticals, Inc. announced its entry into an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A and Horizon Credit LLC II.

Titan Pharmaceuticals, Inc. announced that its partner, Molteni Farmaceutici, has entered into an exclusive distribution agreement with Accord Healthcare Europe for the commercialization of Sixmo®-, the brand name for Probuphine® in the European Union.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A (“Molteni”) and Horizon Credit LLC II (“Horizon”), as well as its agreement to acquire JT Pharmaceuticals, Inc.'s (“JT Pharma”) kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura® long-term,

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into an amendment (the “Amendment”) of the previously announced definitive asset purchase, supply and support agreement (the “Purchase Agreement”) with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®.

Titan and Molteni expect to enter into the definitive license and distribution agreement during the first quarter of 2018.

Titan Pharmaceuticals, Inc. announced that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A.

Probuphine will be marketed in the European Union under the brand name “Sixmo”

Probuphine to be marketed in the European Union under the brand name “Sixmo”

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced the publication of three new, peer-reviewed studies that demonstrate the clinical value of the use of the T2 Biosystems’ products, also referred to as T2 Magnetic Resonance Technology.